Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Chronic Hepatitis C Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females must be post-menopausal for at least 2 years or surgically sterile or practicing specific forms of birth control~* Chronic hepatitis C, genotype 1-infection and HCV RNA level greater than 10,000 IU/mL at screening~* Subject has never received antiviral treatment for hepatitis C infection~* No evidence of liver cirrhosis~Exclusion Criteria:~* Positive screen for drugs or alcohol~* Significant sensitivity to any drug~* Use of contraindicated medications within 2 weeks of dosing~* Certain predefined abnormal laboratory tests~* Positive hepatitis B surface antigen or anti-human immunodeficiency virus antibody

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- ABT-450/r/ABT-267 and ABT-333, plus RBV (Type: EXPERIMENTAL): Double-blind ABT-450/r/ABT-267 (150 mg/100 mg/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
- Placebo Followed by ABT-450/r/ABT-267 and ABT-333, plus RBV (Type: EXPERIMENTAL): Double-blind placebo for 12 weeks, followed by open-label ABT-450/r/ABT-267 (150 mg/100 mg/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).